JAK2 and viral infectious disease: Specifically, MOL004112 and MOL002235 do not show any hepatic, neurotoxic, immunotoxic, mutagenic, or cytotoxic effects, and they are unable to cross the blood–brain barrier (BBB), which is advantageous for developing JAK2 inhibitors for viral infection treatment.